Something unusual is happening in financial markets and it could mean more gains lie ahead for stocks, if history is any indication.Marketsread more
Tesla is working on new battery cell designs, and a way to make their own cells, with R&D teams in a lab near its car plant in Fremont, California.Technologyread more
Underneath the impressive market rally is a trend that doesn't seem quite right, according to J.P. Morgan.Marketsread more
Ten 2020 Democratic presidential candidates will take the debate stage Wednesday at the Adrienne Arsht Center for the Performing Arts in Miami.2020 Electionsread more
See which stocks are posting big moves after the bell on June 26.Market Insiderread more
These attacks have given the public the opportunity to examine the problems associated with ransomware, where corporations -- not obligated to disclose these attacks -- have...Technologyread more
JP Morgan's Jamie Dimon says student lending "is a disgrace and it's hurting America."Economyread more
Online home goods retailer Wayfair sold roughly 1,600 mattresses and 100 bunk beds to Baptist Child and Family Services, a nonprofit that works as a federal contractor...Retailread more
Bitcoin jumped to its highest price since January 2018 on Wednesday.Bitcoinread more
The Federal Reserve and the market are miles apart on interest rate expectations, and the disparity could cost the stock market a 7%-10% drop, economists say.Economyread more
The Senate will try to reconcile its emergency border aid plan with one passed by Nancy Pelosi and House Democrats.Politicsread more
Bluebird Bio CEO Nick Leschly on Friday defended the biotech company's $1.8 million price tag for its new gene therapy to treat a rare genetic blood disorder.
Bluebird's therapy, Zynteglo, was approved in Europe earlier this month for patients with beta thalassemia who require regular blood transfusions to manage their disease and have no matching donor for a stem cell transplant. The price tag, set Friday, makes the drug the second most expensive in the world behind Swiss drugmaker Novartis' $2.1 million gene therapy for spinal muscular atrophy.
Leschly reasoned that the one-time treatment is a game changer for patients, giving them a "lifelong benefit" while avoiding costly blood transfusions every few weeks for the rest of their lives.
Bluebird said patients will only have to pay $1.8 million if the treatment works. The company proposed a five-year installment plan, with 315,000 euros, or $356,567, paid upfront and additional payments due only if the treatment proves effective. It's a form of value-based pricing, Leschly said.
"Neither Novartis' drug nor our drug is anywhere near the most expensive drug in the world. It's really thinking about it differently," Leschly said in an interview on CNBC's "The Exchange. " "This is a good thing, a one time curative treatment."
Novartis and Bluebird's approvals mark a new era in medicine where new therapies can cure patients in a single treatment — but at a high price. Insurers and governments will need to figure out how to pay for these therapies and society will need to decide whether any drug, even lifesaving ones, are worth millions of dollars.
Bluebird expects the therapy to be approved for beta thalassemia in the U.S. in 2020.
In May, Novartis gave a similar reasoning on pricing for its one-time treatment for spinal muscular atrophy, a muscle-wasting disease and leading genetic cause of infant mortality.
In rationalizing the expensive price, Novartis said the one-time treatment costs 50% less than the 10-year cost of current chronic management of the disease. Another current treatment for spinal muscular atrophy for children and adults is Biogen's Spinraza, which has a list price of $750,000 for the first year and $375,000 annually thereafter.